Evidence map›Paper›PMID 33942026›Full record

ArticleKidney international reports2021

Neutralizing Antibody Responses After SARS-CoV-2 Infection in End-Stage Kidney Disease and Protection Against Reinfection.

Luke Muir, Aneesa Jaffer, Chloe Rees-Spear, Vignesh Gopalan, Fernando Y Chang, Raymond Fernando, Gintare Vaitkute, Chloe Roustan, Annachiara Rosa, Christopher Earl and 5 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Kidney international reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 2 pooled it
1.0field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 2 syntheses or guidelines pooled it, 16 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 1 country.

Luke MuirUCL Institute of Immunity & Transplantation, University College London, London, UK.
Aneesa JafferDepartment of Nephrology & Transplantation, Royal Free London NHS Trust, London, UK.
Chloe Rees-SpearUCL Institute of Immunity & Transplantation, University College London, London, UK.
Vignesh GopalanDepartment of Nephrology & Transplantation, Royal Free London NHS Trust, London, UK.
Fernando Y ChangResearch Department of Surgical Biotechnology, UCL Division of Surgery and Interventional Science, University College London, London, UK.
Raymond FernandoDepartment of Nephrology & Transplantation, Royal Free London NHS Trust, London, UK.
Gintare VaitkuteResearch Department of Surgical Biotechnology, UCL Division of Surgery and Interventional Science, University College London, London, UK.
Chloe RoustanThe Francis Crick Institute, London, UK.
Annachiara RosaThe Francis Crick Institute, London, UK.
Christopher EarlThe Francis Crick Institute, London, UK.
Gayathri K RajakarunaCentre for Transplantation, Department of Renal Medicine, University College London, London, UK.
Peter CherepanovThe Francis Crick Institute, London, UK.
Alan SalamaDepartment of Nephrology & Transplantation, Royal Free London NHS Trust, London, UK.
Laura E McCoyUCL Institute of Immunity & Transplantation, University College London, London, UK.
Reza MotallebzadehUCL Institute of Immunity & Transplantation, University College London, London, UK.
University College London · GBRoyal Free London NHS Foundation Trust · GBThe Francis Crick Institute · GB

Funding

Medical Research Council MR/R008698/1
6 · The paper itself

Abstract

introductionPatients with end-stage kidney disease (ESKD) represent a vulnerable group with multiple risk factors that are associated with poor outcomes after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Despite established susceptibility to infectious complications and the importance of humoral immunity in protection against SARS-CoV-2, few studies have investigated the humoral immune response to SARS-CoV-2 within this population. Here, we evaluate the seroprevalence of SARS-CoV-2 in patients awaiting renal transplantation and determine whether seroconverted patients with ESKD have durable and functional neutralizing activity against SARS-CoV-2.

methodsSerum samples were obtained from 164 patients with ESKD by August 2020. Humoral immune responses were evaluated by SARS-CoV-2 spike S1 subunit and nucleoprotein semiquantitative enzyme-linked immunosorbent assay (ELISA) and SARS-CoV-2 spike pseudotype neutralization assay.

resultsAll patients with ESKD with reverse-transcriptase polymerase chain reaction (RT-PCR)-confirmed infection (n = 17) except for 1 individual seroconverted against SARS-CoV-2. Overall seroprevalence (anti-S1 and/or anti-N IgG) was 36% and was higher in patients on hemodialysis (44.2%). A total of 35.6% of individuals who seroconverted were asymptomatic. Seroconversion in the absence of a neutralizing antibody (nAb) titer was observed in 12 patients, all of whom were asymptomatic. Repeat measurements at a median of 93 days from baseline sampling revealed that most individuals retained detectable responses although a significant drop in S1, N and nAb titers was observed.

conclusionPatients with ESKD, including those who develop asymptomatic disease, routinely seroconvert and produce detectable nAb titers against SARS-CoV-2. Although IgG levels wane over time, the neutralizing antibodies remain detectable in most patients, suggesting some level of protection is likely maintained, particularly in those who originally develop stronger responses.

Indexed as

antibodyCOVID-19ESKDhemodialysisneutralization assaySARS-CoV-2

Identifiers

PMID33942026
PMCPMC8081267
OpenAlexW3158656380

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.